GLP-1 RAs were considered excellent candidates for treating COVID-19 also in patients without diagnosis of T2DM owing to their multiple beneficial effects on excessive inflammation-induced acute lung injury [8], once again showing that COVID-19 can be considered a model of acute stressor against which molecules with a marked anti-inflammatory role can act. Here, GLP1R is linked to COVID-19.